MRVI(MRVI)
MRVI
ANALYST COVERAGE13 analysts
HOLD
▲ +28.7%upside to target
L $4.50
Med $5.25consensus
H $6.00PRICE
Prev Close
4.15
Open
4.10
Day Range4.00 – 4.23
4.00
4.23
52W Range1.99 – 5.00
1.99
5.00
70% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
-5.8x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
0.95
Market-like
TECHNICAL
RSI (14)
60
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 105 days
Aug 31
Key MetricsTTM
Market Cap$2.15B
Revenue TTM$204.73M
Net Income TTM-$104.56M
Free Cash Flow-$51.87M
Gross Margin29.0%
Operating Margin21.9%
Net Margin-51.1%
Return on Equity-44.7%
Return on Assets-14.7%
Debt / Equity0.17
Current Ratio5.91
EPS TTM$-0.71
MRVI News
About
Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are global leaders in providing products and services into the fields of nucleic acid production, biologics safety testing, and protein detection to many of the world's leading biopharma, vaccine, diagnostics, and cell and gene therapy companies.
Kate E. BroderickExecutive Vice President
Bernd BrustChief Executive Officer & Director
Chad DeckerSenior Vice President of Sales at TriLink & Alphazyme
Christopher BenoitExecutive Vice President & Advisor
Kurt OreshackExecutive Vice President, General Counsel & Secretary
Rajesh J. AsarpotaExecutive Vice President & Chief Financial Officer
Robert Andrew EckertChairman of the Board
Chanfeng ZhaoSenior Vice President & Chief Scientific Officer
Christine DolanExecutive Vice President & GM of Cygnus Technologies
Debra HartSenior Director of Investor Relations
Judith A. SoleckiSenior VP & Chief Human Resources Officer